Committed to protecting the world against
dangerous and difficult-to-treat infectious diseases
When working in the field of life-threatening infectious diseases, you are racing against rapidly evolving pathogens.
Since our company’s inception, we have focused on getting in front of changing fungal infections that are growing resistant to existing agents and are becoming increasingly deadly.
Today, our research continues as we explore the next-generation antifungals with potentially transformative fungicidal potency against yeasts and molds.
Our eyes are on the future and what’s next.
The structures of the fungerp class of antifungals and echinocandins are very different, allowing for:
The MOA of the novel fungerp antifungals is different from the azoles and polyenes, allowing for: